SOLIGENIX, INC. 8-K

What Happened Soligenix, Inc. (SNGX) filed an 8-K on June 26, 2026 announcing a prospectus supplement that increases the maximum aggregate offering amount of common stock issuable under its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by $2,500,000. The Sales Agreement was originally dated January 23, 2026. A legal opinion regarding the $2.5M of additional shares is attached as Exhibit 5.1 to the filing.

Key Details

• Date filed: June 26, 2026.
• Incremental increase: $2,500,000 to the maximum aggregate amount available under the Sales Agreement.
• Prior sales: the Company previously sold approximately $6,234,000 of common stock under the Sales Agreement, under prior prospectus supplements that covered up to $6,406,000.
• Implied new maximum authorized under the agreement: $6,406,000 + $2,500,000 = $8,906,000 (based on amounts stated in the filing).

Why It Matters This update gives Soligenix additional flexibility to raise capital by selling common stock "at-the-market" into the open market through Rodman & Renshaw. For investors, that means the company has an increased capacity to issue shares quickly if it chooses, which can provide funding for operations or development but can also dilute existing shareholders if shares are sold. The filing is procedural—no immediate shares were reported sold in this 8-K; it simply expands the available amount the company may issue under the existing sales agreement.